RAC2 and myeloid sarcoma: In contrast, increased expression of RAC2 (Ras-related C3 botulinum toxin substrate 2), a Rho GTPase that regulates T-cell activation, dendritic cell migration, and peripheral immune tolerance, is causally associated with lower MS risk, supporting the hypothesis that statins may exert beneficial effects through RAC2-mediated pathways [20].